SEC Form 4 · accession 0001127602-16-046099
UNITED THERAPEUTICS Corp · UTHR
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Martine A Rothblatt
Officer — Chairman & Co-CEO · Director
Period of report
Mar 10, 2016
Accepted (ET)
Mar 11, 2016 · 4:00 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001082554
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2 | Mar 10, 2016 | M | 5,546 | $30.75 | A | 5,786 | D | |
| Common StockF3 | Mar 10, 2016 | S | 3,413 | $122.6715 | D | 2,373 | D | |
| Common StockF4 | Mar 10, 2016 | S | 1,015 | $123.3946 | D | 1,358 | D | |
| Common StockF5 | Mar 10, 2016 | S | 400 | $124.8975 | D | 958 | D | |
| Common StockF6 | Mar 10, 2016 | S | 600 | $125.8916 | D | 358 | D | |
| Common StockF7 | Mar 10, 2016 | S | 118 | $127.3622 | D | 240 | D | |
| Common Stock | holding | — | — | — | 166 | I | By Spouse | |
| Common Stock | holding | — | — | — | 625,031 | I | By Trusts |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Options | $30.75 | Mar 10, 2016 | M | 5,546 | D | Dec 26, 2009 | Dec 31, 2017 | Common Stock | 5,546 | 232,953 | D |
Explanation of responses
- F1This exercise of stock options and corresponding sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person.
- F2Exercise price and number of shares/awards has been adjusted to reflect the issuer's two-for-one stock split on September 22, 2009.
- F3This transaction was executed in multiple trades at prices ranging from $122.12 to $123.055. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F4This transaction was executed in multiple trades at prices ranging from $123.13 to $124.00. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F5This transaction was executed in multiple trades at prices ranging from $124.58 to $125.48. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F6This transaction was executed in multiple trades at prices ranging from $125.59 to $126.40. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F7This transaction was executed in multiple trades at prices ranging from $126.93 to $127.44. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.